Treatment of hyperlactacidemia in cirrhotic patients with pyridoxine-alpha-ketoglutarate (PAK).
After pyridoxine-alpha-ketoglutarate (PAK) was administered to patients with hepatic cirrhosis, the blood level values for lactic acid and ammonia showed a statistically significant reduction. These results suggest that PAK can be used for treatment adn prevention of hyperlactacidemia secondary to chronic hepatopathy.
D000138:Acidosis / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000641:Ammonia / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007773:Lactates / Q000097:blood*; D019344:Lactic Acid; D008103:Liver Cirrhosis / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011736:Pyridoxine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D007773:Lactates; C000503:conductase; D019344:Lactic Acid; D000641:Ammonia; D011736:Pyridoxine